Literature DB >> 16961159

Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality.

A Boyer1, K Chadda, A Salah, D Annane.   

Abstract

Corticosteroids were proposed for the treatment of sepsis as early as 1940. Several RCTs cast serious doubts on the usefulness of high dose corticosteroids and doubt still persists regarding the efficacy of replacement therapy. Adrenal insufficiency (non-responders to the 250 microg corticotropin test: increase in cortisol < 9 microg/dl) is present in about half of patients with septic shock and is associated with higher rates of refractory hypotension and mortality. Peripheral glucocorticoid resistance, which may even occur more frequently, can be easily assessed at bedside using skin tests. Cortisol antagonizes the migration of inflammatory cells, the synthesis or action of virtually all proinflammatory mediators, promotes virtually all anti-inflammatory components and enhances humoral immunity by means of transcriptional interference between its receptor and both AP-1 and NF-kappaB. Cortisol mediates cardiovascular tolerance to endotoxin and the maintenance of vascular sensitivity to catecholamines. Low doses (about 300 mg daily for 5 days or more) of hydrocortisone increase vasoconstrictor response to catecholamines in animals, in healthy volunteers challenged with LPS and in several RCTs. Hydrocortisone also increases arterial pressure and decreases the duration of shock. A meta-analysis of all available clinical controlled studies showed a reduction in 28 days, all-cause mortality with glucocorticoids (RR = 0.88, 95% CI: 0.78 - 1.00; p = 0.04). However, there was a significant heterogeneity across the trials (p = 0.006). On the other hand, analysis of studies where low doses of glucocorticoids were given for prolonged periods showed a 24% reduction in the risk of all-cause mortality at 28 days in treated patients (RR = 0.76, 95% CI: 0.64 - 0.90; p = 0.002) without heterogeneity across the trials (p = 0.28). In conclusion, in severe sepsis, high doses of corticosteroids should not be given. Septic shock should be treated with a replacement dose of hydrocortisone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961159     DOI: 10.5414/cpp44309

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

1.  Mycophenolate mofetil has potent anti-inflammatory actions in a mouse model of acute lung injury.

Authors:  M G Beduschi; C L Guimarães; Z S Buss; E M Dalmarco
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

2.  Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions.

Authors:  Ines Kaufmann; Josef Briegel; Florian Schliephake; Alwin Hoelzl; Alexander Chouker; Theresia Hummel; Gustav Schelling; Manfred Thiel
Journal:  Intensive Care Med       Date:  2007-09-29       Impact factor: 17.440

Review 3.  Interventions for preventing critical illness polyneuropathy and critical illness myopathy.

Authors:  Greet Hermans; Bernard De Jonghe; Frans Bruyninckx; Greet Van den Berghe
Journal:  Cochrane Database Syst Rev       Date:  2014-01-30

4.  Corticosteroids for severe sepsis: an evidence-based guide for physicians.

Authors:  Djillali Annane
Journal:  Ann Intensive Care       Date:  2011-04-13       Impact factor: 6.925

5.  Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013-2016.

Authors:  Wang Ma; Haodi Huang; Jian Chen; Ke Xu; Qigang Dai; Huiyan Yu; Fei Deng; Xian Qi; Shenjiao Wang; Jie Hong; Changjun Bao; Xiang Huo; Minghao Zhou
Journal:  Influenza Other Respir Viruses       Date:  2017-07-26       Impact factor: 4.380

6.  Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study.

Authors:  Michel Pinsard; Stéphanie Ragot; Paul Michel Mertes; Jean Paul Bleichner; Samira Zitouni; Fabrice Cook; Marc Pierrot; Laurent Dube; Edgard Menguy; Laurent Martin Lefèvre; Laurence Escaravage; Pierre-François Dequin; Philippe Vignon; Nicolas Pichon
Journal:  Crit Care       Date:  2014-07-23       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.